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Women with recurrent or metastatic endometrial 
carcinoma who experience disease progression following 
first-line therapy have limited treatment options and a poor 
prognosis. Therefore, new therapies are urgently needed 
for this disease. Recently, data published from a cohort of 
patients included in the phase Ib KEYNOTE-028 clinical 
trial (NCT02054806) that evaluated the activity of the 
PD-1 directed antibody pembrolizumab (10 mg/Kg every 
2 weeks) in patients with PD-L1-positive advanced or 
metastatic endometrial cancer [1]. Among the 75 patients 
screened for PD-L1 expression, 36 (48.0%) had PD-L1-
positive tumors, defined as membranous staining in at 
least 1% of the tumor and associated inflammatory cells 
or positive staining in the stroma. Twelve of the patients 
with PD-L1 positive tumors did not meet the eligibility 
criteria and were excluded; the remaining 24 patients 
were enrolled in the study. After a median follow-up of 
10.9 months, confirmed partial responses were achieved 
in 3 patients (13.0%, 95% confidence interval = 2.8%-
33.6%). Three additional patients (13.0%) had  stable 
disease, with a median duration of 24.6 weeks. The safety 
profile was similar to other pembrolizumab studies, and 
overall, pembrolizumab was well tolerated in this patient 
population.
Although the sample size of this study is small, 
it is worth to highlight that: 1) all the responders had 
endometrioid histology (n = 17), with no objective 
responses among the other 6 patients with different 
subtypes; 2) there is promise for durable clinical activity 
for a subset of patients (26%) with heavily pretreated 
cancers; 62.5% of patients had received ≥ 2 previous 
lines of therapy for advanced disease; 3) the median 
duration of response was not reached, with 2 patients 
still experiencing sustained responses and receiving 
pembrolizumab at the time of the data cutoff; however, 
similar to other cancer subtypes in which PD-1 inhibitors 
have activity, these data suggest that most patients with 
advanced endometrial cancer do not derive benefit 
from PD-1 inhibition given as monotherapy, even those 
with PD-L1 positive tumors. Therefore, the search for 
predictive biomarkers of response that could help to select 
the best candidates for monotherapy is needed.
Genetic aberrations of protein coding DNA in tumor 
cells can generate mutated peptides potentially creating 
neoantigens that, after processing and presentation 
on HLA molecules can be recognized by cytotoxic 
T-cells [2]. High mutational burden has been linked to 
clinical efficacy of immune checkpoint inhibitors in 
melanoma, non-small cell lung cancer (NSCLC) , and 
other malignancies [2], and a higher mutational burden 
correlates with immune cytolytic activity across different 
human cancers [2]. Accordingly, molecular alterations that 
disrupt the capability of a proper DNA replication and are 
associated with an ultra-hyper-mutated phenotype have 
been emerging as predictive biomarkers of response to 
PD-1 inhibitors [3]. Such alterations include inactivating 
mutations in the exonuclease proofreading domains of 
POLE and POLD1 genes, triggering loss of the DNA 
mismatch repair proteins either due to inactivating 
mutations in mismatch repair (MMR) genes (MLH1, 
MSH2, MSH6, PMS2), or due to epigenetic alterations 
resulting in hypermethylation of the MLH1 promoter [3]. 
Data from The Cancer Genome Atlas demonstrated 
that endometrial cancer comprises a heterogeneous 
disease, with the identification of at least 4 molecular 
subtypes including the POLE ultramutated and the 
microsatellite instability (MSI) hyper mutated groups [4] 
.Consistent with the hypothesis that higher mutational/
neoantigen burden is associated with increased 
immunogenicity of tumors, POLE ultra-mutated and 
MSI-high endometrial cancers are richly infiltrated 
with T-cell lymphocytes, have high PD-1 and PD-L1 
expression, and, perhaps, are excellent candidates for 
PD-1/PD-L1 inhibitors [5]. Among the patients included 
in the KEYNOTE-028 trial, all but one of the 19 patients 
tested had MSI-low status. The one patient with MSI-high 
status had disease progression as best response. Genomic 
profiling of the tumor of a patient who experienced a 
partial response after treatment with pembrolizumab 
revealed the presence of a POLE mutation [5]. Other 
reports have shown that different tumors harboring POLE 
or POLD1 mutations are also associated with response to 
PD-1 inhibitors [6, 7]. The FDA recently approved the use 
of pembrolizumab for patients with MSI-high or deficient 
MMR tumors, independent of cancer type [3].
In our opinion the data from this relatively small 
cohort of patients with endometrial cancer from the 
KEYNOTE-028 study point at a signal of activity of 
pembrolizumab in this disease [1]. We do recommend that 
all patients with endometrial cancer undergo a validated 
test to determine their MSI status. POLE mutations as 
predictive biomarkers of response to PD-1inhibitors 
deserve further investigation.
              Editorial
Oncotarget106170www.impactjournals.com/oncotarget
Patrick A. Ott: Department of Medical Oncology, Dana-
Farber Cancer Institute, Boston, MA, USA; Harvard 
Medical School, Boston, MA, USA
Correspondence to: Patrick A. Ott, email patrick_ott@dfci.
harvard.edu
Keywords: endometrial cancer; immunotherapy; PD-1 inhi-
bition; microsatellite instability-high; POLE
Received: October 31, 2017
Published: November 21, 2017
REFERENCES
1. Ott PA, et al. J Clin Oncol. 2017; 35:2535-2541.
2. Schumacher TN, et al. Science. 2015; 348:69-74.
3. Nebot-Bral L, et al. Eur J Cancer. 2017; 84:290-303.
4. Kandoth C, et al. Nature. 2013; 497:67-73.
5. Mehnert JM, et al. J Clin Invest. 2016; 126:2334-2340.
6. Rizvi NA, et al. Science. 2015; 348:124-128.
7. Johanns TM, et al. Cancer Discov. 2016; 6:1230-1236.
Copyright: Barroso-Sousa et al. This is an open-access article 
distributed under the terms of the Creative Commons Attribution 
License 3.0 (CC BY 3.0), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided the original author 
and source are credited.
